Can you discuss study design, rationale, results, and clinical implications of the most recent clinical evidence focused on the safety, immunogenicity, and efficacy of approved biosimilar therapies for RA?

Can you discuss study design, rationale, results, and clinical implications of the most recent clinical evidence focused on the safety, immunogenicity, and efficacy of approved biosimilar therapies for RA?

Can you discuss and explain the study design, rationale, results, and clinical implications of the most recent clinical evidence—i.e. clinical trial—focused on the safety, immunogenicity, and efficacy of approved biosimilar therapies for RA; with a focus on the anti-TNF biosimilar infliximab in the setting of RA, AS, and related conditions?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Jonathan Kay, MD

Jonathan Kay, MD

Director of Clinical Research
Rheumatology Division
Professor of Medicine
University of Massachusetts Medical School
Worcester, MA